Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

被引：0
|
作者：
Yves Horsmans
Jocelyn Zhou
Mateva Liudmila
George Golor
Oren Shibolet
Michelle Quinlan
Corinne Emotte
Hildegard Boss
Henry Castro
Dalila Sellami
Richard A. Preston
机构：
[1] Cliniques Saint-Luc,Early Phase Clinical Unit
[2] UCL St Luc Bruxelles,Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine
[3] Novartis Pharmaceuticals Corporation,Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine
[4] UMHAT “Sveti Ivan Rilski” EAD,undefined
[5] PAREXEL International GmbH,undefined
[6] Tel Aviv Sourasky Medical Center (Ichilov),undefined
[7] Novartis Pharma AG,undefined
[8] University of Miami,undefined
[9] Florida International University,undefined
[10] Bristol Myers Squibb (BMS),undefined
来源：
Clinical Pharmacokinetics | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：345 / 354
页数：9
相关论文
共 50 条
  • [1] Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study
    Horsmans, Yves
    Zhou, Jocelyn
    Liudmila, Mateva
    Golor, George
    Shibolet, Oren
    Quinlan, Michelle
    Emotte, Corinne
    Boss, Hildegard
    Castro, Henry
    Sellami, Dalila
    Preston, Richard A.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 345 - 354
  • [2] Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
    Yin, Ophelia Q. P.
    Gallagher, Neil
    Tanaka, Chiaki
    Fisher, Deirdre
    Sethuraman, Venkat
    Zhou, Wei
    Lin, Tsu-Han
    Heuman, Douglas
    Schran, Horst
    CLINICAL THERAPEUTICS, 2009, 31 : 2459 - 2469
  • [3] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
  • [4] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [5] An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine
    Baird-Bellaire, Susan
    Behrle, Jessica A.
    Parker, Vernon D.
    Patat, Alain
    Paul, Jeffrey
    Nichols, Alice I.
    CLINICAL THERAPEUTICS, 2013, 35 (06) : 782 - 794
  • [6] A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
    Taylor, Lesley
    Crockett, Julie
    Tayo, Bola
    Morrison, Gilmour
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1110 - 1119
  • [7] Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
    Damholt, Birgitte Bentz
    Dombernowsky, Sarah Louise
    Bendtsen, Mette Dahl
    Bisgaard, Charlotte
    Rasmussen, Michael Hojby
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1015 - 1027
  • [8] Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
    Birgitte Bentz Damholt
    Sarah Louise Dombernowsky
    Mette Dahl Bendtsen
    Charlotte Bisgaard
    Michael Højby Rasmussen
    Clinical Pharmacokinetics, 2021, 60 : 1015 - 1027
  • [9] Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
    Lee, C.
    Tang, Y.
    Schroeder, C.
    Zhang, J.
    Nguyen-Cleary, T.
    Mullin, S.
    Ma, M.
    Lyon, N.
    Grundy, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S321 - S322
  • [10] Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
    Kasichayanula, Sreeneeranj
    Liu, Xiaoni
    Zhang, Weijiang
    Pfister, Marc
    LaCreta, Frank P.
    Boulton, David W.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1798 - 1808
12345